Streetbeat News

CING

Cingulate Inc.

https://www.cingulate.com

Industry

Biotechnology

Cingulate Inc., a clinical-stage biopharmaceutical company, focuses on the development of product candidates for the treatment of attention-deficit/hyperactivity disorder. The company's lead product candidates are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, and CTx-1302 (dextroamphetamine) for the treatment of attention-deficit/hyperactivity disorders. It also focuses on developing CTx-2103 for the treatment of anxiety disorders. The company was founded in 2012 and is headquartered in Kansas City, Kansas.

Open

4.19

Mkt cap

13M

Volume

25K

High

4.19

P/E Ratio

-0.09

52-wk high

152.40

Low

4.01

Div yield

N/A

52-wk low

1.80

Cingulate Inc. shares have risen following the announcement that the company received guidance from the FDA on its CTx-1301 clinical program. The company anticipates submitting the New Drug Application (NDA) for CTx-1301 in the first half of 2025.

Portfolio Pulse from Benzinga Newsdesk

December 28, 2023 | 3:18 pm

U.S. stocks opened higher with the Dow Jones gaining over 50 points. Health care shares led gains, while energy shares declined. U.S. initial jobless claims rose to 218,000, above market estimates. Nova LifeStyle, Inc. (NVFY) surged 243%, Cingulate Inc. (CING) jumped 138% after FDA guidance for its ADHD product, and SenesTech, Inc. (SNES) rose 51% following an analyst's buy rating. Conversely, Cytosorbents Corporation (CTSO) fell 36%, Bluejay Diagnostics, Inc. (BJDX) dropped 31% after announcing a public offering, and RiskOn International, Inc. (ROI) declined 27% ahead of an AI platform announcement.

Portfolio Pulse from Avi Kapoor

December 28, 2023 | 3:03 pm

Trading in shares of Cingulate Inc. (CING) has resumed after a temporary halt. The reasons for the halt and the implications for the company and its investors are not detailed in the article.

Portfolio Pulse from Benzinga Newsdesk

December 28, 2023 | 2:52 pm

Cingulate Inc (CING) saw its stock trading higher after receiving FDA guidance for its ADHD drug candidate CTx-1301. The company plans to submit an NDA in 1H 2025 using Novartis AG's (NVS) Focalin XR as a reference. Cingulate has stopped enrollment in two Phase 3 studies and will update its Pediatric Study Plan. It requires $17M-$21M to file the NDA, less than expected. Cingulate is also planning to initiate clinical plans for CTx-1302 and may develop CTx-2103 for anxiety, pending additional capital. The company is addressing Nasdaq compliance issues due to board member resignations and will present a plan at a hearing in February 2024. CING shares surged 174.2% to $10.94.

Portfolio Pulse from Vandana Singh

December 28, 2023 | 2:50 pm

Cingulate's stock (CING) was halted due to a circuit breaker after experiencing a significant drop, but it has since rebounded with an increase of 174.2%.

Portfolio Pulse from Benzinga Newsdesk

December 28, 2023 | 2:48 pm

Cingulate Inc. shares have resumed trading. There is no additional context provided in the article regarding the reason for the halt or the implications of the resumption.

Portfolio Pulse from Benzinga Newsdesk

December 28, 2023 | 2:47 pm

Shares of Cingulate (CING) were halted on a circuit breaker due to a sharp increase in price, with the stock surging 198.8%.

Portfolio Pulse from Benzinga Newsdesk

December 28, 2023 | 2:42 pm

Cingulate (CING) received FDA guidance for its ADHD treatment, CTX-1301, and plans to submit an NDA in H1 2025. SEALSQ (LAES) revealed its post-quantum semiconductor technology to secure crypto transactions against quantum threats. Microbot Medical (MBOT) announced the successful completion of its GLP pivotal pre-clinical study under FDA guidelines using a porcine model.

Portfolio Pulse from ryanfaloona@benzinga.com

December 28, 2023 | 1:42 pm

Bridgeline Digital, Inc. (NASDAQ:BLIN) shares fell by 13.1% in pre-market trading after reporting a narrower-than-expected loss for its fourth quarter but missing sales estimates. Other stocks experienced significant movements in pre-market trading, with Cingulate Inc. (NASDAQ:CING) and SenesTech, Inc. (NASDAQ:SNES) among the top gainers, while Rent the Runway, Inc. (NASDAQ:RENT) and Cyclo Therapeutics, Inc. (NASDAQ:CYTH) were among the top losers.

Portfolio Pulse from Avi Kapoor

December 28, 2023 | 1:22 pm

In Thursday's pre-market session, several healthcare stocks experienced significant movements. Cingulate (CING) saw the largest increase, with shares up 188.5% to $11.51. SenesTech (SNES) and Palisade Bio (PALI) also saw substantial gains of 82.02% and 55.83%, respectively. On the losing side, Bluejay Diagnostics (BJDX) experienced the largest drop, falling 34.5% to $1.15. Other notable decliners include CytoSorbents (CTSO) and First Wave BioPharma (FWBI), with decreases of 32.52% and 15.74%, respectively.

Portfolio Pulse from Benzinga Insights

December 28, 2023 | 1:07 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.